| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Duvakitug targets TNFSF15/TL1A (tumor necrosis factor superfamily member 15), a member of the tumor necrosis factor family. TL1A is expressed in various immune cells, including monocytes, macrophages, dendritic cells, and T cells. By neutralizing TNFSF15/TL1A, Duvakitug reduces intestinal inflammation. The antibody is a humanized IgG1-λ2 monoclonal antibody.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Duvakitug binds to TNFSF15/TL1A with high affinity and specificity. The antibody's binding to TNFSF15 can be assessed using surface plasmon resonance (SPR) or ELISA-based binding assays. The antibody's ability to neutralize TNFSF15 activity can be evaluated in cell-free systems using purified TNFSF15 and its receptor.
|
| ln Vivo |
In cell-based assays, Duvakitug neutralizes TNFSF15/TL1A, reducing intestinal inflammation. The antibody's effects are evaluated in immune cell assays, where TNFSF15-induced signaling and cytokine production are measured. The antibody can be used in the study of Crohn's Disease (CD). Its anti-inflammatory effects are assessed in cell-based models of inflammation.
|
| Enzyme Assay |
The cell-free assay for Duvakitug involves measuring its binding to TNFSF15 protein. This can be performed using surface plasmon resonance (SPR) to determine the binding affinity (KD). ELISA-based binding assays can also be used to assess the antibody's binding to immobilized TNFSF15. The antibody's neutralization activity can be evaluated using cell-free signaling assays with purified TNFSF15 and its receptor.
|
| Cell Assay |
Cell-based assays for Duvakitug involve culturing immune cells and treating them with the antibody at concentrations ranging from 0.1 to 100 μg/mL. Cells are stimulated with TNFSF15 to induce inflammatory responses. The antibody's ability to neutralize TNFSF15 is assessed by measuring the inhibition of downstream signaling and cytokine production. The antibody's effects on intestinal inflammation are evaluated in relevant cell models.
|
| Animal Protocol |
In animal models, Duvakitug has been evaluated for its ability to reduce intestinal inflammation in models of Crohn's Disease. Typical studies involve administration of the antibody to mice via intraperitoneal or intravenous routes. Disease progression is monitored by measuring inflammatory markers, tissue damage, and disease activity scores. The antibody's ability to neutralize TNFSF15 and reduce inflammation is assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Duvakitug are typical of monoclonal antibodies. As a humanized IgG1-λ2 antibody, it is expected to have a long half-life in circulation, typically days to weeks. The antibody is administered via parenteral routes (intravenous). Its distribution is primarily in the vascular space and tissues. The antibody is cleared through proteolytic degradation and Fc receptor-mediated mechanisms.
|
| Toxicity/Toxicokinetics |
Duvakitug is an investigational antibody and its toxicity profile is being evaluated in preclinical and clinical studies. As an immunomodulatory antibody, potential toxicities include immune-related adverse events, infections, and infusion-related reactions. Standard toxicology studies in animal models are conducted to determine the safety profile, maximum tolerated dose, and target organ toxicity.
|
| References | |
| Additional Infomation |
Duvakitug is an investigational monoclonal antibody being developed for the treatment of Crohn's Disease. It targets TNFSF15/TL1A and neutralizes its activity to reduce intestinal inflammation. Clinical trials have been conducted or are planned to evaluate the safety and efficacy of Duvakitug in patients with inflammatory bowel disease. The antibody is not yet approved for clinical use.
|
| CAS # |
2750005-84-4
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
